ORIC Pharmaceuticals Statistics
Total Valuation
ORIC has a market cap or net worth of $779.49 million. The enterprise value is $501.18 million.
| Market Cap | 779.49M |
| Enterprise Value | 501.18M |
Important Dates
The last earnings date was Monday, May 4, 2026, after market close.
| Earnings Date | May 4, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
ORIC has 103.52 million shares outstanding. The number of shares has increased by 36.45% in one year.
| Current Share Class | 103.52M |
| Shares Outstanding | 103.52M |
| Shares Change (YoY) | +36.45% |
| Shares Change (QoQ) | +2.81% |
| Owned by Insiders (%) | 1.23% |
| Owned by Institutions (%) | 95.08% |
| Float | 82.53M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 1.87 |
| P/TBV Ratio | 1.87 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 16.33, with a Debt / Equity ratio of 0.02.
| Current Ratio | 16.33 |
| Quick Ratio | 15.86 |
| Debt / Equity | 0.02 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -42.57% and return on invested capital (ROIC) is -28.80%.
| Return on Equity (ROE) | -42.57% |
| Return on Assets (ROA) | -27.57% |
| Return on Invested Capital (ROIC) | -28.80% |
| Return on Capital Employed (ROCE) | -35.78% |
| Weighted Average Cost of Capital (WACC) | 9.98% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.30M |
| Employee Count | 104 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -19.53% in the last 52 weeks. The beta is 1.06, so ORIC's price volatility has been similar to the market average.
| Beta (5Y) | 1.06 |
| 52-Week Price Change | -19.53% |
| 50-Day Moving Average | 9.33 |
| 200-Day Moving Average | 10.77 |
| Relative Strength Index (RSI) | 35.75 |
| Average Volume (20 Days) | 1,578,664 |
Short Selling Information
The latest short interest is 21.94 million, so 21.20% of the outstanding shares have been sold short.
| Short Interest | 21.94M |
| Short Previous Month | 22.01M |
| Short % of Shares Out | 21.20% |
| Short % of Float | 26.59% |
| Short Ratio (days to cover) | 15.51 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -149.91M |
| Pretax Income | -135.21M |
| Net Income | -135.21M |
| EBITDA | -148.72M |
| EBIT | -149.91M |
| Earnings Per Share (EPS) | -$1.40 |
Balance Sheet
The company has $281.93 million in cash and $6.73 million in debt, with a net cash position of $275.20 million or $2.66 per share.
| Cash & Cash Equivalents | 281.93M |
| Total Debt | 6.73M |
| Net Cash | 275.20M |
| Net Cash Per Share | $2.66 |
| Equity (Book Value) | 415.56M |
| Book Value Per Share | 4.02 |
| Working Capital | 272.46M |
Cash Flow
In the last 12 months, operating cash flow was -$110.88 million and capital expenditures -$327,000, giving a free cash flow of -$111.20 million.
| Operating Cash Flow | -110.88M |
| Capital Expenditures | -327,000 |
| Depreciation & Amortization | 1.19M |
| Net Borrowing | n/a |
| Free Cash Flow | -111.20M |
| FCF Per Share | -$1.07 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
ORIC does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -36.45% |
| Shareholder Yield | -36.45% |
| Earnings Yield | -17.42% |
| FCF Yield | -14.32% |
Analyst Forecast
The average price target for ORIC is $20.36, which is 170.39% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $20.36 |
| Price Target Difference | 170.39% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 16 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 2 |